
4DMedical Limited
FDMDF
Updated: 22/09/2026, 10:41:14
4DMedical Limited operates as a medical technology firm with operations spanning both Australia and the United States. A core aspect of its business involves the commercialization of XV Technology, an advanced four-dimensional system for lung imaging. The company's offerings further extend to a software-as-a-service (SaaS) delivery model, alongside its proprietary XV lung ventilation analysis software. Additional products include Permetium, a preclinical imaging system designed to quantify localized changes in pulmonary function, and the AccuVent 200, a ventilator specifically tailored for small animals. Established in 2012, 4DMedical Limited is headquartered in Carlton, Australia.
No summaries found.
- Share price
- $2.66
- Market cap
- $1.60B
- Exchange
- OTC
- Currency
- USD
- CEO
- Andreas Fouras
- Employees
- 124
- IPO date
- 02/02/2021
- Beta
- 1.965
- Last dividend
- $0.00
- Day range
- $2.47 – $2.66
- 52-week range
- $0.87 – $5.00
- 1-day performance
- 0.00%
- 1-year performance
- 205.85%
- Current drawdown (1Y)
- -46.78%
- CIK
- N/A
- CUSIP
- N/A
- ISIN
- AU0000095416
- Created
- 07/12/2025, 03:56:20
- Last update
- 22/09/2026, 10:41:14
Track 4DMedical Limited with an AI analyst
See which prediction-market events move FDMDF, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.